Figure 1.
Diagram of standard doublet regimens. Standard combination treatment regimens are represented by the bars. Continuously dosed oral drugs are depicted by a solid line and infusion therapies as bars. Treatments that are continued indefinitely until disease progression or intolerable toxicity have an arrow at the right side. All treatment regimens are diagramed to scale with respect to each, with the length of the bar showing time on each drug. Ibrutinib and rituximab (IR) is based on A041202, ibrutinib and obinutuzumab (IO) on iLLUMINATE, acalabrutinib and obinutuzumab (AO) on ELEVATE-TN, venetoclax and obinutuzumab (VO) on CLL14, and venetoclax and ibrutinib on GLOW.3,6,8,10,15

Diagram of standard doublet regimens. Standard combination treatment regimens are represented by the bars. Continuously dosed oral drugs are depicted by a solid line and infusion therapies as bars. Treatments that are continued indefinitely until disease progression or intolerable toxicity have an arrow at the right side. All treatment regimens are diagramed to scale with respect to each, with the length of the bar showing time on each drug. Ibrutinib and rituximab (IR) is based on A041202, ibrutinib and obinutuzumab (IO) on iLLUMINATE, acalabrutinib and obinutuzumab (AO) on ELEVATE-TN, venetoclax and obinutuzumab (VO) on CLL14, and venetoclax and ibrutinib on GLOW.3,6,8,10,15 

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal